News
Important Only
RPT-BREAKINGVIEWS-White House whims create bank capital dilemma
By Stephen Gandel NEW YORK, Jan 12 (Reuters Breakingviews) - For Wall Street, the Trump presidency is a matter of give and take. Shares of the biggest U.S. lenders have surged in anticipation of regulatory relief that would leave them with over $140 billion of excess capital, judging by the avera...Reuters
Tue, Jan 13
RPT-BREAKINGVIEWS-Airline deal flies smoother with fewer passengers
By Jonathan GuilfordNEW YORK, Jan 12 (Reuters Breakingviews) - Deals done at 40,000 feet have a better chance of success with fewer people involved. Airline M&A has been choppy in the United States, but discount carrier Allegiant Travel's ALGT.O plan to buy peer Sun Country Airlines SNCY.O ...Reuters
Tue, Jan 13
RPT-BREAKINGVIEWS-Trump’s imperial Fed push meets its Waterloo
By Gabriel Rubin WASHINGTON, Jan 12 (Reuters Breakingviews) - Jerome Powell, a devotee of the Grateful Dead, knows it costs a lot to win and even more to lose. One day after the passing of guitarist Bob Weir, the Federal Reserve head put this ethos into practice. In an extraordinary Sunday-night ...Reuters
Tue, Jan 13
Sustainable Switch -Climate change, Venezuela and Big Oil
Jan 13 (Reuters) - By Sharon KimathiEnergy and ESG Editor, Reuters Digitalsharon.kimathi@thomsonreuters.com Hello!Venezuela and Big Oil are back in focus in today’s newsletter after major oil companies met with U.S. President Donald Trump last week to discuss plans, while academics at Harvard s...Reuters
Tue, Jan 13
Oramed And Lifeward Announce Strategic Transaction
Jan 13 (Reuters) - Lifeward Ltd 2RW.MU:ORAMED AND LIFEWARD ANNOUNCE STRATEGIC TRANSACTIONORAMED PHARMACEUTICALS INC - TO RECEIVE 49.9% OWNERSHIP IN LIFEWARDORAMED PHARMACEUTICALS INC - MARK GRANT TO LEAD COMBINED PLATFORMSORAMED PHARMACEUTICALS INC - LIFEWARD TO ISSUE $10 MILLION CONVERTIBLE NOTESOR...Reuters
Tue, Jan 13
Trump's Iran tariff threat risks reopening China rift
Trump's 25% Iran duties risks return of trade war with ChinaChinese firms could face levies topping 70% at US borderChina, Tehran's top trade partner, provides an economic lifeline to the Islamic republicBy Joe Cash BEIJING, Jan 13 (Reuters) - U.S. President Donald Trump's threat ...Reuters
Tue, Jan 13
Intensity Therapeutics Highlights 2025 Milestones And Outlines 2026 Strategic Priorities
Jan 13 (Reuters) - Intensity Therapeutics Inc INTS.O:INTENSITY THERAPEUTICS HIGHLIGHTS 2025 MILESTONES AND OUTLINES 2026 STRATEGIC PRIORITIESINTENSITY THERAPEUTICS INC - PLANS TO FILE PROTOCOL AMENDMENT FOR INVINCIBLE-4 STUDY AND REINITIATE ENROLLMENT IN Q1 2026INTENSITY THERAPEUTICS INC: TO RAISE A...Reuters
Tue, Jan 13
US FDA approves Fortress Bio and Zydus' treatment for a rare pediatric disease
Jan 13 (Reuters) - The U.S Food and Drug Administration approved Fortress Biotech FBIO.O and Indian drugmaker Zydus Lifesciences' ZYDU.NS drug for a type of rare genetic disease in children, Fortress said on Tuesday.Reuters
Tue, Jan 13
Euda Enters Into Convertible Loan Agreement With Shenzhen Inno, Further Expanding Stem Cell Therapy Platform
Jan 13 (Reuters) - EUDA Health Holdings Ltd EUDA.O:EUDA ENTERS INTO CONVERTIBLE LOAN AGREEMENT WITH SHENZHEN INNO, FURTHER EXPANDING STEM CELL THERAPY PLATFORMEUDA HEALTH HOLDINGS LTD - TO INVEST UP TO RMB 6 MILLION IN TWO TRANCHESReuters
Tue, Jan 13
FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms
Jan 13 (Reuters) - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers imposing a 100% tariff on imported branded and patented medicines. Although enforcement is delayed for companies investing in U.S. manufacturing, the policy...Reuters
Tue, Jan 13
Amneal Pharma Expects To Meet Or Exceed Its 2025 Full-Year Financial Guidance
Jan 13 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O:AMNEAL PHARMA: EXPECTS TO MEET OR EXCEED ITS 2025 FULL-YEAR FINANCIAL GUIDANCEFY2025 EARNINGS PER SHARE VIEW $0.80, REVENUE VIEW $3.01 BILLION -- LSEG IBES DATAFurther company coverage: AMRX.OReuters
Tue, Jan 13
Fortress Biotech And Cyprium Therapeutics Announce U.S. FDA Approval Of Zycubo® (Copper Histidinate), The First And Only Approved Treatment For Menkes Disease In The United States
Jan 13 (Reuters) - Fortress Biotech Inc FBIO.O:FORTRESS BIOTECH AND CYPRIUM THERAPEUTICS ANNOUNCE U.S. FDA APPROVAL OF ZYCUBO® (COPPER HISTIDINATE), THE FIRST AND ONLY APPROVED TREATMENT FOR MENKES DISEASE IN THE UNITED STATESFORTRESS BIOTECH INC - CYPRIUM ELIGIBLE FOR UP TO $129 MILLION IN MILESTON...Reuters
Tue, Jan 13
REFILE-ANALYSIS-Trump’s exercise of raw power upends world order, sending friends and foes reeling
By Matt Spetalnick, John Geddie and Antoni SlodkowskiWASHINGTON/TOKYO/LONDON/BEIJING/MEXICO CITY, Jan 13 (Reuters) - He has toppled Venezuela’s leader, vowed to control its vast oil reserves and threatened other Latin American countries with similar military action. He has talked openly about annexi...Reuters
Tue, Jan 13
PREVIEW-Davos begins new era grappling with global order shaken by Trump
WEF meeting follows US moves on business, diplomacyFirst Davos meeting since founder Schwab stood downInternational cooperation tested by 'America First'By Dave Graham ZURICH, Jan 13 (Reuters) - Business and political elites head to the World Economic Forum's annual meeting in Davos n...Reuters
Tue, Jan 13
CX services provider Concentrix's Q4 adjusted EPS beats expectations
OverviewGlobal tech service leader's Q4 revenue slightly beat analyst expectationsAdjusted EPS for Q4 beat analyst expectationsCompany returned $258 mln to shareholders in fiscal 2025 via dividends and buybacksOutlookConcentrix forecasts Q1 revenue between $2.475 bln and $2.5 blnCompany expects ...Reuters
Tue, Jan 13
TotalEnergies evaluating options on Venezuela - CEO
PARIS, Jan 13 (Reuters) - The chief executive of TotalEnergies TTEF.PA Patrick Pouyanne said on Tuesday the group, which like several other oil giants left Venezuela in recent years, was evaluating its options in the country. "People want to rush back to Venezuela but it will require a clear...Reuters
Tue, Jan 13
Amerigo Reports Record Q4-2025 Operational Results, Exceeds Revised 2025 Production Target And Provides 2026 Guidance
Jan 13 (Reuters) - Amerigo Resources Ltd ARG.TO:AMERIGO REPORTS RECORD Q4-2025 OPERATIONAL RESULTS, EXCEEDS REVISED 2025 PRODUCTION TARGET AND PROVIDES 2026 GUIDANCEAMERIGO RESOURCES LTD - Q4-2025 COPPER PRODUCTION OF 18.9 MILLION POUNDSAMERIGO RESOURCES LTD - 2026 GUIDANCE OF 63.8 MILLION POUNDS OF...Reuters
Tue, Jan 13
